Edition:
India

Agile Therapeutics Inc (AGRX.OQ)

AGRX.OQ on NASDAQ Stock Exchange Global Market

4.86USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
41,911
52-wk High
$7.03
52-wk Low
$1.82

Latest Key Developments (Source: Significant Developments)

Agile Therapeutics Q3 loss per share $0.22
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Agile Therapeutics Inc :Agile therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.22.Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Agile Therapeutics Inc - PDUFA goal date for Twirla is December 26, 2017​.Agile Therapeutics - ‍believes cash, cash equivalents as of sept. 30, will be sufficient to meet its operating requirements into Q2 of 2018​.  Full Article

Agile Therapeutics board appointed CEO Al Altomari as chairman of board
Friday, 7 Oct 2016 

Agile Therapeutics Inc : On October 5, 2016, board appointed Al Altomari, president and CEO, as chairman of board effective immediately - SEC filing Source: (http://bit.ly/2dOmS1B) Further company coverage: [AGRX.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Agile Therapeutics enters into first amendment to loan, security agreement with Hercules Capital, other banks, other financial institutions
Saturday, 27 Aug 2016 

Agile Therapeutics Inc : Entered into first amendment to loan and security agreement with Hercules Capital, Inc, other banks,other financial institutions . First amendment extends interest-only payments until January 31, 2017 in connection with first tranche of $16.5 million of term loan .Amendment extends co's option to draw down second tranche of $8.5 million of term loan facility provided under loan agreement until Mar 31,2017.  Full Article

Agile Therapeutics reports Q2 loss per share $0.29
Tuesday, 9 Aug 2016 

Agile Therapeutics Inc : Agile Therapeutics reports second quarter 2016 financial results . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.29 . Says as of june 30, 2016 $59.2 million of cash and cash equivalents compared to $34.4 million as of december 31, 2015 .Says cash and cash equivalents will be sufficient to meet its operating requirements through end of 2017.  Full Article

Agile Therapeutics reports Q1 loss per share $0.27
Tuesday, 10 May 2016 

Agile Therapeutics Inc : Cash expected to fund operations through end of 2017 . Agile therapeutics reports first quarter 2016 financial results . Q1 loss per share $0.27 .Q1 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article

Agile Therapeutics Inc announces proposed offering of common stock
Friday, 22 Jan 2016 

Agile Therapeutics Inc:Intends to offer and sell $30 million of shares of its common stock.  Full Article

BRIEF-Agile Therapeutics Q3 loss per share $0.22

* Agile therapeutics reports third quarter 2017 financial results